

Navicixizumab (Synonyms: OMP 305B83 [WHO-DD])



Catalog Number: 176937

Product name

Navicixizumab (Synonyms: OMP 305B83 [WHO-DD])

Specificity

Human DLL4

Antibody description

Anti-DLL4 Antibody (Navicixizumab)

Preparation

Recombinant expression and purified from CHO cells.

Formulation

0.1 M Pro-Ac, 20 mM Arg, pH 5.0

Storage

-80°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.

Clonality

Monoclonal


Ig Type

IgG2SA

Applications


ELISA

Validations




SDS-PAGE

Anti-DLL4 Antibody (navicixizumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



SEC-HPLC

The purity of Anti-DLL4 Antibody (navicixizumab) is more than 95%, determined by SEC-HPLC.



Bioactivity: ELISA

Immobilized human VEGF165 His at 2 µg/mL can bind Anti-DLL4 Antibody (navicixizumab), EC50=0.01191 µg/mL.